Tuesday, October 4, 2022


Biotechnology News Magazine

Dr. Jordan Dubow Appointed CMO of Paragon Biosciences

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

Dr. Jordan Dubow will be responsible for identifying and evaluating innovation opportunities utilizing his clinical and regulatory expertise and providing guidance to Paragon Biosciences seven portfolio companies.

Headquartered in Chicago, Paragon Biosciences is a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence.

“At Paragon Biosciences, our mission of solving complex human and societal challenges requires the assembling of top-tier talent,” said Jeff Aronin, founder, chairman and CEO, Paragon Biosciences. “With the addition of Jordan to our team of remarkable innovators, Paragon continues to accelerate the development of novel therapies and life science breakthroughs.”

Prior to joining Paragon, Dr. Dubow was the chief medical officer at Avadel Pharmaceuticals. He also was vice president of CNS Therapeutic Strategy at Esteve Pharmaceuticals, responsible for evaluating in-licensing candidates and provided regulatory and clinical support for its development pipeline. Dr. Dubow served as vice president of clinical and medical affairs at Clintrex. He has held leadership positions at Cynapsus Therapeutics and started his pharmaceutical career at AbbVie as a medical director in neuroscience clinical development. He has played a pivotal role on nine new drug applications (NDAs) in the U.S. as well as numerous NDAs in Europe, Japan, Canada, and Australia.

Dr. Dubow began his career as an academic board-certified neurologist focusing on Parkinson’s disease and vascular neurology. He completed medical school and a neurology residency at the Northwestern University Feinberg School of Medicine, a movement disorders fellowship at a Northwestern University-affiliated hospital and a vascular neurology fellowship at New York Presbyterian/Weil Cornell Medical Center.

“With the numerous promising studies underway at its portfolio companies, Paragon Biosciences continues to make impressive strides to help people with high unmet medical needs,” said Jordan Dubow, M.D., chief medical officer, Paragon Biosciences. “My work at Paragon Biosciences has the potential to positively impact people and the world we live in. It is incredible to have a supporting role with this life science innovator.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine